Codeine

證據等級: L5

預測適應症: 4 個

Codeine: From Opioid Analgesia to Nasal Cavity Disease

One-Sentence Summary

Codeine (DB00318) is a well-established mu-opioid receptor agonist widely used as an analgesic and antitussive, though formal indication data was not captured in this Evidence Pack. The TxGNN model predicts it may have activity in Nasal Cavity Disease (score: 99.93%), with 0 clinical trials and 2 publications retrieved — however, both publications describe codeine as a cause of nasal pathology, not a treatment. This pattern repeats across all four predicted indications and represents a likely directionality error in the knowledge graph, warranting a Hold recommendation across the board.

Quick Overview

Item	Content
Original Indication	No formal regulatory record in this dataset; codeine is widely established as an opioid analgesic and antitussive
Predicted New Indication	Nasal Cavity Disease
TxGNN Prediction Score	99.93%
Evidence Level	L5
US Market Status	Not captured (0 regulatory licenses retrieved)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, codeine is a prodrug metabolized by CYP2D6 to morphine, acting primarily as a mu-opioid receptor (MOR) agonist. Its established clinical uses include analgesia, cough suppression, and management of diarrhea — all mediated via central and peripheral opioid receptors.

The TxGNN model likely established a link between codeine and nasal cavity disease because the knowledge graph contains a high density of co-occurrence between codeine and nasal pathology. However, reviewing the two retrieved publications reveals a classic directionality error: both describe codeine (or related opioids) as the cause of nasal injury. One case series documents intranasal abuse of hydrocodone-acetaminophen leading to mucosal necrosis; the other reports a rhinolith formed around an “opioma” — a foreign body composed of codeine and opium. Neither provides any evidence of a therapeutic effect on nasal cavity disease.

In short, the knowledge graph connection reflects “codeine → nasal disease” (harm pathway), whereas a valid drug repurposing hypothesis requires “codeine → treats nasal disease” (therapeutic pathway). These two relationships are fundamentally different, and the model cannot distinguish between them at the prediction stage.

Clinical Trial Evidence

Currently no related clinical trials registered for Codeine in Nasal Cavity Disease.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22965281	2012	Case Report	The Laryngoscope	Intranasal abuse of hydrocodone-acetaminophen (crushing and snorting tablets) leads to mucosal necrosis of the nasal cavity and pharynx — codeine-class opioid as the cause of disease, not treatment
17315836	2007	Case Report	Ear, Nose, & Throat Journal	Rhinolithiasis formed around an impacted “opioma” (hardened codeine + opium foreign body) causing nasal obstruction and purulent rhinorrhea — opioid substance as a mechanical cause of nasal pathology

⚠️ Critical Note: Both publications document codeine/opioids as etiological agents of nasal pathology, not as therapeutic interventions. The high TxGNN score almost certainly reflects knowledge graph co-occurrence of codeine with nasal disease in an adverse/causal context — a directionality error rather than a therapeutic signal.

US Market Information

No regulatory license records were retrieved for Codeine in this dataset (0 licenses; query returned no results). This is likely a data collection gap rather than reflecting the actual US market status. Codeine is known to be available in the United States in various combination products (e.g., codeine-acetaminophen, codeine-containing cough preparations) as well as Schedule II single-entity formulations.

Please refer to the FDA Orange Book or DailyMed for current authorization details.

Safety Considerations

Please refer to the package insert for safety information.

⚠️ Known Safety Concern (from general pharmacological knowledge, not this dataset): Codeine carries an FDA Black Box Warning for respiratory depression, particularly in CYP2D6 ultra-metabolizers who convert codeine to morphine at an accelerated rate. This risk is especially severe in children and post-tonsillectomy/adenoidectomy patients. Any repurposing investigation must account for this population-specific safety profile.

Conclusion and Next Steps

Decision: Hold

Rationale: All four TxGNN-predicted indications for Codeine share the same fundamental problem: the knowledge graph connection reflects codeine as a cause or confounder rather than a therapeutic agent for the predicted disease. This constitutes a systemic directionality error across the entire prediction set, making none of the four candidates suitable for progression.

Predicted Indication	Why It Fails
Nasal Cavity Disease	Both publications show opioid-induced nasal necrosis; reverse causality
Acute Laryngopharyngitis	Zero evidence; antitussive effect is an existing use, not repurposing
Trigeminal Autonomic Cephalalgia	5 case reports all document opioid use as patient background, not as treatment; EHF/AHS guidelines explicitly recommend against opioids in TAC; MOH risk
Allergic Urticaria	15 publications consistently identify codeine as a mast cell degranulator and urticaria trigger, not treatment; codeine is used as a positive control in urticaria skin testing

To proceed, the following is needed:

Directionality audit of the knowledge graph: Distinguish “codeine causes disease X” edges from “codeine treats disease X” edges before running future predictions for this drug class
MOA data (DG002): Retrieve full mechanism-of-action profile from DrugBank API to enable proper mechanistic link analysis
US regulatory data: Retrieve actual FDA license records (Orange Book / DailyMed) to complete the market status picture
Alternative indication search: If repurposing potential is desired for codeine, consider redirecting the analysis toward indications where opioid receptors play a clearly therapeutic (not harmful) mechanistic role — and focus on indications beyond codeine’s already-approved uses (analgesia, antitussive, antidiarrheal)
Safety framework: Any future candidate should pre-specify a CYP2D6 genotyping strategy and respiratory monitoring plan given the Black Box Warning profile
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.